Boceprevir: all 42 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)CompletedNCT01945294Phase 3Results posted
• Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis CCompletedNCT01925183Phase 4Results posted
• Dutch Acute HCV in HIV Study (DAHHS)CompletedNCT01912495Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)CompletedNCT01756079Phase 4Results posted
• HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /RibavirinTerminatedNCT01718301Phase 3Results posted
• Boceprevir and Ucalm (St John&Apos;s Wort)CompletedNCT01663922Phase 1Results posted
• A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis CCompletedNCT01591460Phase 4Results posted
• Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed TreatmentCompletedNCT01585584Phase 3Results posted
• Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)CompletedNCT01544920Phase 3Results posted
• The Boceprevir and Sildenafil Pharmacokinetics StudyCompletedNCT01499498Phase 1Results posted
• Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV InfectionCompletedNCT01482767Phase 3Results posted
• Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIVTerminatedNCT01443923Phase 4Results posted
• Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative VolunteersCompletedNCT01427504Not applicableResults posted
• The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)CompletedNCT01425203Phase 3Results posted
• Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)TerminatedNCT01425190Phase 1Results posted
• Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)CompletedNCT01390844Phase 3Results posted
• Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)CompletedNCT01181804Phase 1Results posted
• A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)CompletedNCT00959699Phase 2Results posted
• Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)CompletedNCT00910624Phase 3Results posted
• Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)CompletedNCT00845065Phase 3Results posted
• Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)CompletedNCT00708500Phase 3Results posted
• Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)CompletedNCT00705432Phase 3Results posted
• Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)TerminatedNCT00689390Phase 2/3Results posted
• Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)CompletedNCT00423670Phase 2Results posted
• Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)CompletedNCT00160251Phase 2Results posted
• Boceprevir Treatment in Liver Pre-transplant HCV PatientsStatus unknownNCT02160080Phase 3
• Comparative Effectiveness and Tolerability of Boceprevir vs TelaprevirCompletedNCT02113631Not applicable
• Boceprevir in End Stage Renal Disease (ESRD)WithdrawnNCT02112630Not applicable
• A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCVStatus unknownNCT01949168Phase 2
• Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver TransplantationCompletedNCT01909401Early Phase 1
• A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)WithdrawnNCT01770223Phase 4
• A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)Status unknownNCT01731301Phase 4
• Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult SubjectsCompletedNCT01657552Phase 1
• Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C InfectionStatus unknownNCT01653236Phase 3
• Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)WithdrawnNCT01641666Phase 3
• Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy SubjectsCompletedNCT01597895Phase 1
• Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy SubjectsCompletedNCT01471717Phase 1/2
• Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)CompletedNCT01470690Phase 1
• Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver TransplantationCompletedNCT01463956Phase 2
• Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)Status unknownNCT01457937Phase 3
• Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/RibavirinCompletedNCT01335529Phase 2
• Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor RaltegravirCompletedNCT01288417Phase 1

← Boceprevir overview